Home›Articles›ZUMA-7 and the move to earlier use of axicabtagene ciloleucelArticleZUMA-7 and the move to earlier use of axicabtagene ciloleucelArticlesConnectionsSourcesComments (0)Reader Challenges (0)ConnectionsArticle OnAxicabtagene ciloleucel, Drugs and Medicinal Substances Well-attested SourcesAxicabtagene ciloleucel (Wikipedia)HistoryQuote, HistoryIn the ZUMA-7 trial, patients treated with axicabtagene ciloleucel had superior clinical outcomes compared with the previous standard of care, including improved overall survival with an estimated 4-year overall survival rate of 54.6% for axicabtagene ciloleucel, compared with 46% for the previous standard of care.View the SourceMedicine Atlas Original Articlestier 1Comments (0)No comments yet. Be the first to share a thought.Sign in to join the discussion.Reader Challenges (0)No disputes yet. Spotted an error or a better source? Open the first one.Sign in to dispute this or suggest a correction.